CagriSema Shows Greater Weight Loss and Metabolic Benefits compared to monotherapies: Study

A new study published in the journal of Diabetes, Metabolic Syndrome and Obesity showed that CagriSema resulted in more significant weight loss and enhancements in glucose and lipid regulation in comparison to regular single treatments and a dummy pill.

Excessive weight, obesity, and diabetes are growing health challenges worldwide. Semaglutide enhances blood sugar management and encourages weight reduction, while cagrilintide, a synthetic version of amylin, works through different but complementary ways. The combination of CagriSema aims to offer improved metabolic advantages by incorporating both medications. Nevertheless, there is a lack of extensive data comparing CagriSema with individual treatments and inactive treatments. This analysis examines the effectiveness and safety of CagriSema based on recent randomized controlled trials.

This review and meta-analysis adhered to the PRISMA 2020 guidelines and was registered in PROSPERO in advance. PubMed, Embase, MEDLINE, and Cochrane Library were examined until June 14, 2026, with no limitations on language. 8 suitable RCTs, involving individuals with overweight/obesity or type 2 diabetes, were incorporated. The risk of bias was evaluated employing RoB 2. The study examined outcomes such as body weight, cardiometabolic parameters, and safety. Separate pairwise meta-analyses were conducted utilizing random-effects models. The effect estimates comprised MDs, ETRs, and RRs with 95% CIs. Heterogeneity was analyzed using I², and the certainty of the findings was assessed using GRADE.

A total of 6898 participants were included in the analysis, where CagriSema showed a significant increase in the percentage of body weight loss when compared to semaglutide, cagrilintide, and placebo.

A greater reduction in the percentage of glycated hemoglobin was also noted for CagriSema in comparison to semaglutide, cagrilintide, and placebo. Additionally, CagriSema led to significantly higher decreases in absolute body weight, waist circumference, and body mass index across all groups (all p < 0.0001).

CagriSema exhibited superior control of blood pressure compared to cagrilintide and placebo, with effects similar to those of semaglutide. Furthermore, CagriSema notably lowered C-reactive protein levels and enhanced lipid profiles in contrast to cagrilintide and placebo.

CagriSema resulted in increased overall adverse events and gastrointestinal issues when compared to all other groups. Considerable variability in statistical outcomes was observed due to differences in baseline clinical characteristics and treatments.

Overall, CagriSema (2.4 mg/2.4 mg) led to more significant decreases in body weight (both in percentage and absolute values), waist circumference, and BMI compared to semaglutide monotherapy, cagrilintide monotherapy, and placebo.

Reference:

Shao, C., Lin, H., Yu, J., Chen, H., Ren, Y., Ren, J., Zeng, Y., Wu, Y., Bai, H., Zhang, Q., & Xiao, X. (2026). Efficacy and safety of CagriSema for metabolic outcomes: Systematic review and pairwise meta-analysis of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 19, 616418. https://doi.org/10.2147/DMSO.S616418